SCYNEXIS (SCYX) 10-Q 12 May 22 2022 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2022	May 01, 2022
Cover [Abstract]
Entity Registrant Name	SCYNEXIS, Inc.
Trading Symbol	SCYX
Entity Central Index Key	0001178253
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Document Type	10-Q
Document Period End Date	Mar. 31, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q1
Amendment Flag	false
Entity Common Stock, Shares Outstanding		32,579,491
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Shell Company	false
Entity File Number	001-36365
Entity Tax Identification Number	56-2181648
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	1 Evertrust Plaza
Entity Address, Address Line Two	13th Floor
Entity Address, City or Town	Jersey City
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	07302-6548
City Area Code	201
Local Phone Number	884-5485
Document Quarterly Report	true
Document Transition Report	false
Title of Each Class	Common Stock, par value $0.001 per share
Name of Each Exchange on Which Registered	NASDAQ

Unaudited Condensed Consolidate

Unaudited Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 95,210	$ 104,484
Prepaid expenses and other current assets	3,919	3,569
Accounts receivable, net	1,628	861
Inventory	1,149	463
Total current assets	101,906	109,377
Other assets	5,543	6,122
Deferred offering costs	124	150
Restricted cash	218	218
Property and equipment, net	61	113
Intangible assets, net	961	1,056
Operating lease right-of-use asset (See Note 7)	2,749	2,801
Total assets	111,562	119,837
Current liabilities:
Accounts payable	8,130	7,848
Accrued expenses	4,523	5,698
Other liabilities, current portion (See Note 6)	174	0
Warrant liabilities	40	0
Operating lease liability, current portion (See Note 7)	77	70
Total current liabilities	12,944	13,616
Other liabilities (See Note 6)	4,102	3,345
Warrant liabilities	7,921	18,062
Convertible debt and derivative liability (See Note 6)	10,817	11,607
Loan payable	33,713	28,745
Operating lease liability (See Note 6)	3,138	3,204
Total liabilities	72,635	78,579
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value, authorized 5,000,000 shares as of March 31, 2022 and December 31, 2021; 0 shares issued and outstanding as of March 31, 2022 and December 31, 2021	0	0
Common stock, $0.001 par value, 100,000,000 shares authorized as of March 31, 2022 and December 31, 2021; 29,221,158 and 28,705,334 shares issued and outstanding as of March 31, 2022 and December 31, 2021, respectively	32	32
Additional paid-in capital	403,825	400,705
Accumulated deficit	(364,930)	(359,479)
Total stockholders’ equity	38,927	41,258
Total liabilities and stockholders’ equity	$ 111,562	$ 119,837

Unaudited Condensed Consolida_2

Unaudited Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2022	Dec. 31, 2021
Statement Of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	29,221,158	28,705,334
Common stock, shares outstanding (in shares)	29,221,158	28,705,334

Unaudited Condensed Consolida_3

Unaudited Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Revenue:
Total revenue	$ 687	$ 12,050
Operating expenses:
Cost of product revenues	99	0
Research and development	5,735	6,948
Selling, general and administrative	14,591	6,696
Total operating expenses	20,425	13,644
Loss from operations	(19,738)	(1,594)
Other expense (income):
Loss on extinguishment of debt	0	2,725
Amortization of debt issuance costs and discount	390	256
Interest income	(13)	(7)
Interest expense	1,059	214
Other income	(13)	0
Warrant liabilities fair value adjustment	(10,030)	(1,296)
Derivative liabilities fair value adjustment	(980)	90
Total other (income) expense	(9,587)	1,982
Loss before taxes	(10,151)	(3,576)
Income tax (benefit) expense	(4,700)	1,100
Net loss	$ (5,451)	$ (4,676)
Net loss per share attributable to common stockholders – basic
Net loss per share – basic	$ (0.17)	$ (0.18)
Net loss per share attributable to common stockholders – diluted
Net loss per share – diluted	$ (0.18)	$ (0.23)
Weighted average common shares outstanding – basic and diluted
Basic	32,051,228	25,802,700
Diluted	33,189,428	26,523,920
Product Revenue, Net
Revenue:
Total revenue	$ 687	$ 0
License Agreement Revenue
Revenue:
Total revenue	$ 0	$ 12,050

Unaudited Condensed Consolida_4

Unaudited Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash flows from operating activities:
Net loss	$ (5,451)	$ (4,676)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	155	27
Stock-based compensation expense	922	398
Amortization of debt issuance costs and discount	390	256
Change in fair value of warrant liabilities	(10,030)	(1,296)
Change in fair value of derivative liabilities	(980)	90
Noncash operating lease expense for right-of-use asset	52	49
Loss on extinguishment of debt	0	2,725
Changes in operating assets and liabilities:
Prepaid expenses, accounts receivable, inventory, and other	(1,429)	1,736
Accounts payable, accrued expenses, other liabilities, and other	383	(68)
Net cash used in operating activities	(15,988)	(759)
Cash flows from investing activities:
Purchase of intangible assets	(9)	(200)
Net cash used in by investing activities	(9)	(200)
Cash flows from financing activities:
Proceeds from common stock issued	2,164	0
Payments of offering costs and underwriting discounts and commissions	(451)	(62)
Proceeds from loan payable	5,000	0
Proceeds from employee stock purchase plan issuances	10	6
Repurchase of shares to satisfy tax withholdings	0	(15)
Net cash provided by (used in) financing activities	6,723	(71)
Net decrease in cash, cash equivalents, and restricted cash	(9,274)	(1,030)
Cash, cash equivalents, and restricted cash at beginning of period	104,702	93,314
Cash, cash equivalents, and restricted cash at end of period	95,428	92,284
Supplemental cash flow information:
Cash paid for interest	1,099	420
Cash received for interest	12	5
Noncash financing and investing activities:
Common stock issued for settlement of senior convertible notes	0	7,452
Purchased intangible assets included in accounts payable and accrued expenses	0	178
Deferred offering and issuance costs included in accounts payable and accrued expenses	26	0
Deferred offering costs reclassified to additional-paid-in capital	27	0
Reclass of warrant liability to additional paid in capital	71	0
Reclass of deferred asset associated with issuance of loan payable to debt discount	$ 206	$ 0

Description of Business and Bas

Description of Business and Basis of Preparation	3 Months Ended
	Mar. 31, 2022
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Description of Business and Basis of Preparation	1. Description of Business and Basis of Preparation Organization SCYNEXIS, Inc. (“SCYNEXIS” or the “Company”) is a Delaware corporation formed on November 4, 1999. SCYNEXIS is a biotechnology company, headquartered in Jersey City, New Jersey, and is pioneering innovative medicines to potentially help millions of patients worldwide in need of new options to overcome and prevent difficult-to-treat and drug-resistant infections. The Company is developing its lead product candidate, ibrexafungerp, as a broad-spectrum, intravenous (“IV”)/oral agent for multiple fungal indications in both the community and hospital settings. In June 2021, the U.S. Food and Drug Administration (“FDA”) approved BREXAFEMME (ibrexafungerp tablets) for treatment of patients with vulvovaginal candidiasis (“VVC”), also known as vaginal yeast infection, and the Company has commenced the commercialization of BREXAFEMME in the U.S. The Company has incurred significant losses and negative cash flows from operations since its initial public offering in May 2014 and expects to continue to incur losses and negative cash flows for the foreseeable future. As a result, the Company had an accumulated deficit of $364.9 million at March 31, 2022 and limited capital resources to fund ongoing operations. These capital resources primarily comprised cash and cash equivalents of $95.2 million at March 31, 2022. While the Company believes its capital resources are sufficient to fund the Company’s on-going operations for a period of at least 12 months subsequent to the issuance of the accompanying unaudited condensed consolidated financial statements, the Company's liquidity could be materially affected over this period by, among other things: (1) its ability to raise additional capital through equity offerings, debt financings, or other non-dilutive third-party funding; (2) costs associated with new or existing strategic alliances, or licensing and collaboration arrangements; (3) negative regulatory events or unanticipated costs related to its development of ibrexafungerp; (4) its ability to commercialize BREXAFEMME and; (5) any other unanticipated material negative events or costs. One or more of these events or costs could materially affect the Company’s liquidity. If the Company is unable to meet its obligations when they become due, the Company may have to delay expenditures, reduce the scope of its research and development programs, or make significant changes to its operating plan. The accompanying unaudited interim condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. The unaudited interim condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. Intercompany balances and transactions are eliminated in consolidation. New Jersey Technology Business Tax Certificate Transfer (NOL) Program The New Jersey Technology Business Tax Certificate Transfer (NOL) program, administered by the New Jersey Economic Development Authority, enables approved biotechnology companies to sell their unused net operating losses (“NOLs”) and research and development tax credits to unaffiliated, profitable corporate taxpayers in the State of New Jersey. For the three months ended March 31, 2022, the Company recognized a $4.7 million income tax benefit for the sale of a portion of the Company’s unused New Jersey NOLs and research and development credits. Unaudited Interim Condensed Consolidated Financial Information The accompanying unaudited interim condensed consolidated financial statements and notes have been prepared in accordance with accounting principles generally accepted in the United States (“US GAAP”), as contained in the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (the “Codification” or “ASC”) for interim financial information. In the opinion of management, the interim financial information includes all adjustments of a normal recurring nature necessary for a fair presentation of the results of operations, financial position, and cash flows. The results of operations for the three months ended March 31, 2022, are not necessarily indicative of the results for the full year or the results for any future periods. These unaudited condensed consolidated financial statements should be read in conjunction with the financial statements and notes set forth in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 29, 2022. Use of Estimates The preparation of unaudited condensed consolidated financial statements in conformity with US GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. Significant estimates and judgements include: revenue recognition including gross to net estimates and the identification of performance obligations in licensing arrangements, determination of the fair value of stock-based compensation grants; the estimate of services and effort expended by third-party research and development service providers used to recognize research and development expense; and the estimates and assumptions utilized in measuring the fair values of the warrant and derivative liabilities each reporting period.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies The accompanying unaudited condensed consolidated financial statements and notes follow the same significant accounting policies as those described in the notes to the audited consolidated financial statements of the Company for the year ended December 31, 2021, except as described below. Basic and Diluted Net Loss per Share of Common Stock The Company calculates net loss per common share in accordance with ASC Earnings Per Share Earnings Per Share, Three Months Ended March 31, 2022 2021 Net loss $ (5,451 ) $ (4,676 ) Dilutive effect of warrant liability — (1,323 ) Dilutive effect of convertible debt (584 ) — Net loss allocated to common shares $ (6,035 ) $ (5,999 ) Weighted average common shares outstanding – basic 32,051,228 25,802,700 Dilutive effect of warrant liability — 721,220 Dilutive effect of convertible debt 1,138,200 — Weighted average common shares outstanding – diluted 33,189,428 26,523,920 Net loss per share – diluted $ (0.18 ) $ (0.23 ) The following potentially dilutive shares of common stock have not been included in the computation of diluted net loss per share for the three months ended March 31, 2022 and 2021, as the result would be anti-dilutive: Three Months Ended March 31, 2022 2021 Outstanding stock options 2,050,094 1,371,606 Outstanding restricted stock units 981,841 96,974 Warrants to purchase common stock associated with June 2016 public offering — 421,867 Warrants to purchase common stock associated with March 2018 public offering – Series 2 798,810 798,810 Warrants to purchase common stock associated with December 2019 Public Offering — 4,472,205 Warrants to purchase common stock associated with December 2020 Public Offering - Series 2 6,800,000 6,800,000 Warrants to purchase common stock associated with Loan Agreement 198,819 — Warrants to purchase common stock associated with Solar loan agreement — 12,243 Common stock associated with March 2019 Notes — 1,138,200 Warrants to purchase common stock associated with Danforth 50,000 — Total 10,879,564 15,111,905 Recently Issued Accounting Pronouncements In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). The amendments in ASU 2016-13 require a financial asset (or group of financial assets) measured at amortized cost basis to be presented at the net amount expected to be collected. In November 2019, the FASB issued ASU No. 2019-10, Financial Instruments – Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) (“ASU 2019-10”), which revised the effective dates for ASU 2016-13 for public business entities that meet the SEC definition of a smaller reporting company to fiscal years, and interim periods within those fiscal years, beginning after December 15, 2022, with early adoption permitted. As a smaller reporting company, the Company is currently evaluating the impact ASU 2016-13 will have on its unaudited interim condensed consolidated financial statements. In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options and Derivatives and Hedging—Contracts in Entity’s Own Equity: Accounting for Convertible Instruments and Contracts in and Entity’s Own Equity (“ASU 2020-06”). The amendments in ASU 2020-06 reduce the number of accounting models for convertible debt instruments and revises certain guidance relating to the derivative scope exception and earnings per share. The amendments in ASU 2020-06 are effective for public business entities that meet the definition of a SEC filer and a smaller reporting company for fiscal years beginning after December 15, 2023, and interim periods within those years. As a smaller reporting company, the Company is currently evaluating the impact ASU 2020-06 will have on its unaudited interim condensed consolidated financial statements.

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	3 Months Ended
	Mar. 31, 2022
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]
Prepaid Expenses and Other Current Assets	3 . Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consisted of the following (in thousands): March 31, 2022 December 31, 2021 Prepaid research and development services $ 753 $ 247 Prepaid insurance 206 505 Other prepaid expenses 2,956 2,813 Other current assets 4 4 Total prepaid expenses and other current assets $ 3,919 $ 3,569

Inventory

Inventory	3 Months Ended
	Mar. 31, 2022
Inventory Disclosure [Abstract]
Inventory	4 . Inventory Inventory consisted of the following (in thousands): March 31, 2022 December 31, 2021 Raw materials $ 5,486 $ 5,162 Work in process 3 3 Finished goods 115 127 Total inventory $ 5,604 $ 5,292 As of March 31, 2022 and December 31, 2021, the Company’s inventory consisted of $4.5 million and $4.8 million, respectively, of raw material that is not expected to be sold in one year and is classified as long term within other assets on the unaudited interim condensed consolidated balance sheet

Accrued Expenses

Accrued Expenses	3 Months Ended
	Mar. 31, 2022
Payables And Accruals [Abstract]
Accrued Expenses	5 . Accrued Expenses Accrued expenses consisted of the following (in thousands): March 31, 2022 December 31, 2021 Accrued research and development expenses $ 1,210 $ 1,498 Accrued employee bonus compensation 505 2,012 Other accrued expenses 1,893 1,352 Accrued co-pay rebates 915 836 Total accrued expenses $ 4,523 $ 5,698

Borrowings

Borrowings	3 Months Ended
	Mar. 31, 2022
Debt Disclosure [Abstract]
Borrowings	6 . Borrowings Loan Agreement On May 13, 2021 (the “Closing Date”), the Company entered into a Loan and Security Agreement (the “Loan Agreement”) with Hercules Capital, Inc. (“Hercules”), as administrative agent and collateral agent (in such capacity, the “Agent”) and a lender, and Silicon Valley Bank, as a lender (“SVB,” and collectively with Hercules, the “Lenders”) for an aggregate principal amount of $60.0 million (the “Term Loan”). Pursuant to the Loan Agreement, the Term Loan is available to the Company in four tranches, subject to certain terms and conditions. Under the terms of the Loan Agreement, the Company received an initial tranche of $20.0 million from the Lenders on the Closing Date. The second tranche of the Term Loan, consisting of up to an additional $10.0 million, became available to the Company upon receipt of approval from the FDA of ibrexafungerp for the treatment of vaginal yeast infections (the “First Performance Milestone”) and was fully funded in June 2021. The third tranche of the Term Loan, consisting of an additional $5.0 million, became available to the Company upon (a) the First Performance Milestone and (b) the achievement of the primary endpoint from the Phase 3 study of ibrexafungerp in patients with recurrent vulvovaginal candidiasis, and was fully funded in March 2022. The fourth tranche of the Term Loan, consisting of up to an additional $25.0 million, will be available to the Company from January 1, 2022 through December 31, 2023 in $5.0 million increments, subject to certain terms and conditions, including in maintaining a ratio of total outstanding Term Loan principal to net product revenues for BREXAFEMME below a certain specified level for a given draw period. The Company estimated the fair value of the loan payable using a credit spread valuation model and Level 3 inputs which included an implied secured spread, risk free rate, and secured yield of 9.63%, 2.44%, and 12.07%, respectively. At March 31, 2022 and December 31, 2021, the fair value of the loan payable is $33.1 million and $29.2 million, respectively. The Term Loan will mature on March 3, 2025 (the “Maturity Date”); provided that, the Maturity Date shall be automatically extended to May 1, 2025 subject to the occurrence of certain conditions set forth in the Loan Agreement. The Term Loan bears interest at a variable annual rate equal to the greater of (a) 9.05% and (b) the Prime Rate (as reported in the Wall Street Journal) plus 5.80% (the “Interest Rate”). The Company may make payments of interest only through November 1, 2023, which may be extended to May 1, 2024 upon the achievement of the First Performance Milestone prior to November 1, 2023, and which is further extendable in quarterly increments until the Maturity Date, subject to continued compliance with the financial covenant of the Loan Agreement (the “interest-only period”). After the interest-only period, the principal balance and related interest will be required to be repaid in equal monthly installments and continuing until the Maturity Date. The Loan Agreement contains customary closing fees, prepayment fees and provisions, events of default, and representations, warranties and covenants, including a financial covenant requiring the Company to maintain certain levels of trailing three-month net product revenue solely from the sale of ibrexafungerp commencing on June 30, 2022. The financial covenant will be waived at any time in which the Company maintains unrestricted and unencumbered cash in accounts maintained with SVB equal to at least 50.0% of the total outstanding Term Loan principal amount, subject to certain requirements. Future principal debt payments on the currently outstanding loan payable as of March 31, 2022 are as follows (in thousands): 2021 $ — 2022 — 2023 — 2024 23,874 2025 11,126 Total principal payments 35,000 Final fee due at maturity 1,383 Total principal and final fee payment 36,383 Unamortized discount and debt issuance costs (2,670 ) Less current portion — Loan payable, long term $ 33,713 April 2020 Note Purchase Agreement On April 9, 2020, the Company entered into the April 2020 Note Purchase Agreement with Puissance Life Science Opportunities Fund VI (“Puissance”) and issued and sold to Puissance $10.0 million aggregate principal amount of its April 2020 Notes, resulting in net proceeds of approximately $9.5 million after deducting $0.5 million for an advisory fee and other issuance costs. In January 2021, Puissance converted the remaining $6.0 million of the April 2020 Notes for 959,080 shares of common stock. Upon conversion of the $6.0 million of the April 2020 Notes, the Company recognized a $2.7 million extinguishment loss which represents the difference between the total net carrying amount of the convertible debt and derivative liability of $4.8 million and the fair value of the consideration issued of $7.5 million. March 2019 Note Purchase Agreement On March 7, 2019, the Company entered into a Senior Convertible Note Purchase Agreement (the “March 2019 Note Purchase Agreement”) with Puissance. Pursuant to the March 2019 Note Purchase Agreement, on March 7, 2019, the Company issued and sold to Puissance $16.0 million aggregate principal amount of its 6.0% Senior Convertible Notes due 2025 ( “March 2019 Notes”) , resulting in $ 14.7 million in net proceeds after deducting $ 1.3 million for an advisory fee and other issuance costs. As of March 31, 2022 and December 31, 2021, the Company’s March 2019 Notes consists of the convertible debt balance of $10.4 million and $10.2 million, presented net of the unamortized debt issuance costs allocated to the convertible debt of $0.3 million, and the bifurcated embedded conversion option derivative liability of $0.4 million and $1.4 million, respectively. In connection with the Company’s issuance of its March 2019 Notes, the Company bifurcated the embedded conversion option, inclusive of the interest make-whole provision and make-whole fundamental change provision, and recorded the embedded conversion option as a long-term derivative liability in the Company’s balance sheet in accordance with ASC 815, Derivatives and Hedging The convertible debt and derivative liability associated with the March 2019 Notes are presented in total on the accompanying unaudited condensed consolidated balance sheets as the convertible debt and derivative liability. The derivative liability will be remeasured at each reporting period using the binomial lattice model with changes in fair value recorded in the statements of operations in other (income) expense. The Company estimated the fair value of the convertible debt and derivative liability for the March 2019 Notes using a binomial lattice valuation model and Level 3 inputs. At March 31, 2022 and December 31, 2021, the fair value of the convertible debt and derivative liability for the March 2019 Notes is $10.9 million and $12.3 million, respectively. The March 2019 Notes were issued and sold for cash at a purchase price equal to 100% of their principal amount, in reliance on the exemption from registration The holder of the March 2019 Notes may convert their March 2019 Notes at their option at any time prior to the close of business on the business day immediately preceding March 15, 2025 into shares of the Company’s common stock. The initial conversion rate is 73.9096 shares of common stock per $1,000 principal amount of March 2019 Notes, which is equivalent to an initial conversion price of approximately $13.53 and is subject to adjustment in certain events described in the March 2019 Note Purchase Agreement. The Holder upon conversion may also be entitled to receive, under certain circumstances, an interest make-whole payment payable in shares of common stock. In addition, following certain corporate events that occur prior to the maturity date, the Company will, in certain circumstances, increase the conversion rate if the holder elects to convert its March 2019 Notes in connection with such a corporate event. Subject to adjustment in the conversion rate, the number of shares that the Company may deliver in connection with a conversion of the March 2019 Notes, including those delivered in connection with an interest make-whole payment, will not exceed a cap of 81 shares of common stock per $1,000 principal amount of the March 2019 Notes. On or after March 15, 2022, the Company has the right, at its election, to redeem all or any portion of the March 2019 Notes not previously converted if the last reported sale price per share of common stock exceeds 130% of the conversion price on each of at least 20 trading days (whether or not consecutive) during the 30 consecutive trading days ending on, and including, the trading day immediately before the date the Company sends the related redemption notice. The redemption price will be 100% of the principal amount of the March 2019 Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. If a “fundamental change” (as defined in the March 2019 Note Purchase Agreement) occurs, then, subject to certain exceptions, the Company must offer to repurchase the March 2019 Notes for cash at a repurchase price of 100% of the principal amount of the March 2019 Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the repurchase date. Other Liabilities In February 2021, the Company partnered with Amplity Inc. (“Amplity”) for the commercial launch of ibrexafungerp for the treatment of VVC. Under the terms of the 5-year agreement, the Company will utilize Amplity’s commercial execution expertise and resources for sales force, remote engagement, training, market access and select operations services. The Company will maintain full ownership of ibrexafungerp and control of all strategic aspects of the launch. Amplity is deferring a portion of its direct service fees (“Deferred Fees”) in the first two years (2021 and 2022), up to a cap, which the Company will repay over three years starting in 2023. As of March 31, 2022 and December 31, 2021, Deferred Fees of $4.1 million and $3.3 million, respectively, are recognized as long term other liabilities in the unaudited interim condensed consolidated balance sheet and represent a debt obligation The Deferred Fees will accrue until the earlier of (i) the cap is reached or (ii) December 31, 2022. The Deferred Fees will accrue interest at annual rate of 12.75% and will be compounded quarterly, at the end of each quarter. Interest expense is recognized using the effective interest method. The Company will repay the Deferred Fees plus accrued interest in quarterly installments at the end of each calendar quarter beginning in 2023. The total amount of Deferred Fees plus accrued interest as of December 31, 2022, will serve as the basis for repayment (the “Repayment Basis”), which shall be repaid in equal installments at the end of a given quarter calculated as follows: 15% of the Repayment Basis will be repaid in 2023; 50% of the Repayment Basis will be repaid in 2024; and 35% of the Repayment Basis will be repaid in 2025. As of March 31, 2022, the Company is obligated to repay $0.7 million in 2023, $2.1 million in 2024, and $1.5 million in 2025. Amplity has the potential to earn a performance-based success fee (“Success Premium”) in the 2023-2025 time frame by exceeding certain revenue targets. The Company identified the Success Premium as a derivative under ASC 815 that qualified for a scope exception given the revenue targets are considered the predominant underlying of the Success Premium. For the three months ended March 31, 2022 and 2021, there was no expense recognized associated with the Success Premium, respectively

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2022
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	7 . Commitments and Contingencies Leases On March 1, 2018, the Company entered into a long-term lease agreement for approximately 19,275 square feet of office space in Jersey City, New Jersey, that the Company identified as an operating lease under ASC 842 (the “Lease”). The lease term is eleven years from August 1, 2018, the commencement date, with total lease payments of $7.3 million over the lease term. The Company has the option to renew for two consecutive five-year in the accompanying unaudited condensed consolidated balance sheets . The consideration in the Lease allocated to the single lease component includes the fixed payments for the right to use the office space as well as common area maintenance. The Lease also contains costs associated with certain expense escalation, property taxes, insurance, parking, and utilities which are all considered variable payments and are excluded from the operating lease liability. The incremental borrowing rate utilized approximated the prevailing market interest rate the Company would incur to borrow a similar amount equal to the total Lease payments on a collateralized basis over the term of the Lease. The following table summarizes certain quantitative information associated with the amounts recognized in the unaudited condensed consolidated financial statements for the Lease (dollars in thousands): Three Months Ended March 31, 2022 2021 Operating lease cost $ 166 $ 166 Variable lease cost (3 ) (2 ) Total operating lease expense $ 163 $ 164 Cash paid for amounts included in the measurement of operating lease liability $ 174 $ 170 March 31, 2022 December 31, 2021 Remaining Lease term (years) 7.34 7.59 Discount rate 15 % 15 % Future minimum lease payments for the Lease as of March 31, 2022 are as follows (in thousands): March 31, 2022 2022 $ 354 2023 715 2024 730 2025 744 2026 759 Thereafter 2,030 Total $ 5,332 The presentations of the operating lease liability as of March 31, 2022 are as follows (in thousands): March 31, 2022 Present value of future minimum lease payments $ 3,215 Operating lease liability, current portion $ 77 Operating lease liability, long-term portion 3,138 Total operating lease liability $ 3,215 Difference between future minimum lease payments and discounted cash flows $ 2,117 License Arrangement with Potential Future Expenditures As of March 31, 2022, the Company had a license arrangement with Merck Sharp & Dohme Corp., or Merck, as amended, that involves potential future expenditures. Under the license arrangement, executed in May 2013, the Company exclusively licensed from Merck its rights to ibrexafungerp in the field of human health. In January 2014, Merck assigned the patents related to ibrexafungerp that it had exclusively licensed to the Company. Ibrexafungerp is the Company's lead product candidate. Pursuant to the terms of the license agreement, Merck was originally eligible to receive milestone payments from the Company that could total $19.0 million upon occurrence of specific events, including initiation of a Phase 3 clinical study, new drug application, and marketing approvals in each of the U.S., major European markets, and Japan. In addition, Merck is eligible to receive tiered royalties from the Company based on a percentage of worldwide net sales of ibrexafungerp. The aggregate royalties are mid- to high-single digits. In December 2014, the Company and Merck entered into an amendment to the license agreement that deferred the remittance of a milestone payment due to Merck, such that no amount would be due upon initiation of the first Phase 2 clinical trial of a product containing the ibrexafungerp compound (the “Deferred Milestone”). The amendment also increased, in an amount equal to the Deferred Milestone, the milestone payment that would be due upon initiation of the first Phase 3 clinical trial of a product containing the ibrexafungerp compound. In December 2016 and January 2018, the Company entered into second and third amendments to the license agreement with Merck which clarified what would constitute the initiation of a Phase 3 clinical trial for the purpose of milestone payment. In January 2019, a milestone payment became due to Merck as a result of the initiation of the VANISH Phase 3 VVC program and was paid in March 2019. On December 2, 2020, the Company entered into a fourth amendment to the license agreement with Merck. The amendment eliminates two cash milestone payments that the Company would have paid to Merck upon the first filing of an NDA, triggered by the FDA acceptance for filing of the Company’s NDA for ibrexafungerp for the treatment of VVC, and first marketing approval in the U.S. Such cash milestone payments would have been creditable against future royalties owed to Merck on net sales of ibrexafungerp. With the amendment, these milestones will not be paid in cash and, accordingly, credits will not accrue. Pursuant to the amendment, the Company will also forfeit the credits against future royalties that it had accrued from a prior milestone payment already paid to Merck. All other key terms of the license agreement are unchanged. Clinical Development Arrangements The Company has entered into, and expects to continue to enter into, contracts in the normal course of business with various third parties who support its clinical trials, preclinical research studies, and other services related to its development activities. The scope of the services under these agreements can generally be modified at any time, and the agreement can be terminated by either party after a period of notice and receipt of written notice.

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2022
Equity [Abstract]
Stockholders' Equity	8 . Stockholders’ Equity Authorized, Issued, and Outstanding Common Stock The Company’s authorized common stock has a par value of $0.001 per share and consists of 100,000,000 shares as of March 31, 2022, and December 31, 2021; 29,221,158 and 28,705,334 shares were issued and outstanding at March 31, 2022, and December 31, 2021, respectively. The following table summarizes common stock share activity for the three months ended March 31, 2022 and 2021 (dollars in thousands): Three Months Ended March 31, 2022 Shares of Common Stock Common Stock Additional Paid-in Capital Accumulated Deficit Total Stockholders’ Equity Balance, December 31, 2021 28,705,334 $ 32 $ 400,705 $ (359,479 ) $ 41,258 Net loss — — — (5,451 ) (5,451 ) Stock-based compensation expense — — 922 — 922 Common stock issued, net of expenses 487,610 — 2,135 — 2,135 Common stock issued through employee stock purchase plan 3,120 — 10 — 10 Common stock issued for vested restricted stock units 25,094 — (18 ) — (18 ) Vested Loan Agreement warrants — — 71 71 Balance, March 31, 2022 29,221,158 $ 32 $ 403,825 $ (364,930 ) $ 38,927 Three Months Ended March 31, 2021 Shares of Common Stock Common Stock Additional Paid-in Capital Accumulated Deficit Total Stockholders’ Equity Balance, December 31, 2020 19,663,698 $ 20 $ 349,351 $ (326,613 ) $ 22,758 Net loss — — — (4,676 ) (4,676 ) Stock-based compensation expense — — 398 — 398 Common stock issued for conversion of April 2020 Notes 959,080 1 7,452 — 7,453 Common stock issued through employee stock purchase plan 2,184 — 6 — 6 Common stock issued for vested restricted stock units 675 — (15 ) — (15 ) Balance, March 31, 2021 20,625,637 $ 21 $ 357,192 $ (331,289 ) $ 25,924 Shares Reserved for Future Issuance The Company had reserved shares of common stock for future issuance as follows: March 31, 2022 December 31, 2021 Outstanding stock options 2,050,094 1,542,126 Outstanding restricted stock units 981,841 133,834 Warrants to purchase common stock associated with March 2018 Public Offering – Series 2 798,810 798,810 Warrants to purchase common stock associated with December 2020 Public Offering - Series 2 6,800,000 6,800,000 Prefunded warrants to purchase common stock associated with December 2020 Public Offering 3,200,000 3,200,000 Warrants to purchase common stock associated with Loan Agreement 198,819 170,410 Warrant to purchase common stock associated with Danforth 50,000 50,000 For possible future issuance for the conversion of the March 2019 Notes 1,138,200 1,138,200 For possible future issuance under 2014 Plan (Note 9) 150,114 295,220 For possible future issuance under Employee Stock Purchase Plan 3,714 3,893 For possible future issuance under 2015 Plan (Note 9) 147,250 235,000 Total common shares reserved for future issuance 15,518,842 14,367,493 Common Stock Purchase Agreement and Sales Agreement On April 10, 2020, the Company entered into the Common Stock Purchase Agreement with Aspire Capital pursuant to which the Company has the right to sell to Aspire Capital from time to time in its sole discretion up to $20.0 million in shares of the Company’s common stock over the next 30 months, subject to certain limitations and conditions set forth in the Common Stock Purchase Agreement. The aggregate number of shares that we can sell to Aspire Capital under the Common Stock Purchase Agreement may in no case exceed 1,956,547 shares of the Company’s common stock (which is equal to approximately 19.99% of the common stock outstanding on the date of the Common Stock Purchase Agreement), including the 70,910 commitment shares (the Exchange Cap), unless either (a) shareholder approval is obtained to issue more, in which case the Exchange Cap will not apply, or (b) the average purchase price of all shares sold under the Common Stock Purchase Agreement exceeds $8.461; provided that at no time shall Aspire Capital (together with its affiliates) beneficially own more than 19.99% of the Company’s common stock. During the three months ended March 31, 2022, the Company sold 350,000 of its common stock under the Common Stock Purchase Agreement for gross proceeds of $1.5 million and did not sell any common stock during the three months ended March 31, 2021. During the months ended March 31, 2022, the Company sold 137,610 shares of its common stock and received net proceeds of $0.7 million, and did not sell any common stock during the three months ended March 31, 2021 under the Controlled Equity Offering SM Cantor Fitzgerald & Co. Ladenburg Thalmann & Co. Inc. Warrants Associated with the March 2018 and December 2020 Public Offerings The outstanding warrants associated with the March 2018 and December 2020 public offerings contain a provision where the warrant holder has the option to receive cash, equal to the Black-Scholes fair value of the remaining unexercised portion of the warrant, as cash settlement in the event that there is a fundamental transaction (contractually defined to include various merger, acquisition or stock transfer activities). Due to this provision, ASC 480, Distinguishing Liabilities from Equity, Warrants Associated with Loan Agreement In connection with the entry into the Loan Agreement, the Company issued to each of Hercules and SVB a warrant (collectively, the “Warrants”) to purchase shares of the Company’s common stock, par value $0.001 per share (the “Shares”). The amount of shares that may be purchased for the Warrants, collectively between Hercules and SVB, will not exceed 0.04 multiplied by the aggregate amount of the term loan advances, divided by the exercise price of the Warrants. At the closing of the Loan Agreement, the Company issued 113,607 warrants to purchase shares of the Company’s common stock and recognized the initial warrants at their relative fair value in shareholder's equity. Upon the funding of the $ 10.0 million and $ 5.0 million for the second and third tranches in June 2021 and March 2022, respectively, the associated warrant liabilities of $ 0.3 million and $ 0.1 million, respectively, were reclassed to additional paid in capital at settlement. In June 2021 and March 2022, 56,803 and 28,409 warrants to purchase shares of the Company’s common stock were issued upon vesting of the second and third tranches, respectively.

Stock-based Compensation

Stock-based Compensation	3 Months Ended
	Mar. 31, 2022
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-based Compensation	9 . Stock-based Compensation Pursuant to the terms of the Company’s 2014 Equity Incentive Plan (“2014 Plan”), on January 1, 2022 and 2021, the Company automatically added 1,148,213 and 786,547 shares to the total number shares of common stock available for future issuance under the 2014 Plan, respectively. As of March 31, 2022, there were 150,114 shares of common stock available for future issuance under the 2014 Plan. As of March 31, 2022, there were 147,250 shares of common stock available for future issuance under the Company’s 2015 Inducement Award Plan (“2015 Plan”). During the three months ended March 31, 2022 and 2021, there were options to purchase 69,000 and zero shares of the Company’s common stock granted under the 2015 Plan, respectively. On April 30, 2021, the Company’s board of directors amended the 2015 Plan, and the share reserve for the 2015 Plan was increased from 90,000 to 500,000 shares of common stock. The activity for the Company’s 2009 Stock Option Plan, 2014 Plan, and 2015 Plan, for the three months ended March 31, 2022, is summarized as follows: Number of Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life (in years) Aggregate Intrinsic Value ($000) Outstanding — December 31, 2021 1,542,126 $ 14.89 7.45 $ 42 Granted 550,500 $ 4.59 Forfeited/Cancelled (42,532 ) $ 7.44 Outstanding — March 31, 2022 2,050,094 $ 12.28 7.97 $ — Exercisable — March 31, 2022 793,216 $ 21.77 6.01 $ — Vested or expected to vest — March 31, 2022 2,050,094 $ 12.28 7.97 $ — Restricted stock unit (“RSU”) activity under the 2014 Plan and 2015 Plan for the three months ended March 31, 2022, is summarized as follows: Number of Shares Weighted Average Grant Date Fair Value Per Share Non-vested at December 31, 2021 133,834 $ 7.98 Granted 883,465 $ 5.59 Vested (25,094 ) $ 7.92 Forfeited (10,364 ) $ 7.60 Non-vested at March 31, 2022 981,841 $ 5.83 The fair value of RSUs is based on the market price of the Company’s common stock on the date of grant. RSUs generally vest 25% annually over a four-year Upon vesting, the RSUs are net share settled to cover the required withholding tax with the remaining shares issued to the holder. The Company recognizes compensation expense for such awards ratably over the corresponding vesting period. Compensation Cost The compensation cost that has been charged against income for stock awards under the 2014 Plan and the 2015 Plan was $0.9 million and $0.4 million for the three months ended March 31, 2022 and 2021, respectively. The total income tax benefit recognized in the statements of operations for share-based compensation arrangements was zero for each of the three months ended March 31, 2022 and 2021. Stock-based compensation expense related to stock options is included in the following line items in the accompanying unaudited condensed consolidated statements of operations (in thousands): Three Months Ended March 31, 2022 2021 Research and development $ 285 $ 126 Selling, general and administrative 637 272 Total $ 922 $ 398

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements	10 . Fair Value Measurements The carrying amounts of certain financial instruments, including cash and cash equivalents, restricted cash, accounts receivable, prepaid expenses and other current assets, accounts payable, and accrued expenses approximate their respective fair values due to the short-term nature of such instruments. Assets and Liabilities Measured at Fair Value on a Recurring Basis The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level in which to classify them for each reporting period. This determination requires significant judgments to be made. The following table summarizes the conclusions reached as of March 31, 2022 and December 31, 2021 for financial instruments measured at fair value on a recurring basis (in thousands): Fair Value Hierarchy Classification Balance Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) March 31, 2022 Cash $ 621 $ 621 — — Restricted cash 218 218 — — Money market funds 94,589 94,589 — — Total assets $ 95,428 $ 95,428 — — Warrant liabilities $ 7,961 — — $ 7,961 Derivative liability 378 — — 378 Total liabilities $ 8,339 — — $ 8,339 December 31, 2021 Cash $ 310 $ 310 — — Restricted cash 218 218 — — Money market funds 104,187 104,187 — — Total assets $ 104,715 $ 104,715 — — Warrant liabilities $ 18,062 — — $ 18,062 Derivative liabilities 1,358 — — 1,358 Total liabilities $ 19,420 — — $ 19,420 The Company measures cash equivalents at fair value on a recurring basis. The fair value of cash equivalents is determined based on “Level 1” inputs, which consist of quoted prices in active markets for identical assets. Level 3 financial liabilities consist of the warrant liabilities for which there is no current market such that the determination of fair value requires significant judgment or estimation. Changes in fair value measurements categorized within Level 3 of the fair value hierarchy are analyzed each period based on changes in estimates or assumptions and recorded as appropriate. The Company uses the Black-Scholes option valuation model to value the Level 3 warrant liabilities at inception and on subsequent valuation dates. This model incorporates transaction details such as the Company’s stock price, contractual terms, maturity, risk free rates, as well as volatility. The unobservable input for all of the Level 3 warrant liabilities includes volatility. The historical and implied volatility of the Company, using its closing common stock prices and market data, is utilized to reflect future volatility over the expected term of the warrants. At March 31, 2022, the range and weighted average of the Level 3 volatilities utilized in the Black-Scholes model to fair value the warrant liabilities were 81.7% to 84.1% and 84.1%, respectively. The Company utilizes a probability assessment to estimate the likelihood of vesting for the remaining Loan Agreement warrants and allocated the probability of occurrence percentage to the fair values calculated. The Company uses the binomial lattice valuation model to value the Level 3 derivative liabilities at inception and on subsequent valuation dates. This model incorporates transaction details such as the Company’s stock price, contractual terms, dividend yield, risk-free rate, adjusted equity volatility, credit rating, market credit spread, and estimated effective yield. The unobservable inputs associated with the Level 3 derivative liabilities are adjusted equity volatility, market credit spread, and estimated yield. As of March 31, 2022, these inputs were 61.4%, 1,463 basis points, and 17.1%, respectively. The senior convertible notes are initially fair valued using the binomial lattice model and with the straight debt fair value calculated using the discounted cash flow method. The discount for lack of marketability, 2.9% as of March 31, 2022, is applied to the value of the March 2019 Notes. The residual difference represents the fair value of the embedded derivative liabilities and the fair value of the embedded derivative liabilities are reassessed using the binomial lattice valuation model on a quarterly basis A reconciliation of the beginning and ending balances for liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows (in thousands): Warrant Liabilities Balance – December 31, 2021 $ 18,062 Loan Agreement warrants (71 ) Gain adjustment to fair value (10,030 ) Balance – March 31, 2022 $ 7,961 Derivative Liabilities Balance – December 31, 2021 $ 1,358 Gain adjustment to fair value (980 ) Balance – March 31, 2022 $ 378

Revenue

Revenue	3 Months Ended
	Mar. 31, 2022
Revenue From Contract With Customer [Abstract]
Revenue	1 1 . Revenue Product Revenue, Net Net product revenue was $0.7 million for the three months ended March 31, 2022. Products are sold primarily to wholesalers and specialty pharmacies. Revenue is reduced from wholesaler list price at the time of recognition for expected chargebacks, rebates, discounts, incentives, and returns, which are referred to as gross to net (“GTN”) adjustments. These reductions are currently attributed to various commercial arrangements. Chargebacks and discounts are recognized as a reduction in accounts receivable or as accrued expenses based on their nature and settled through the issuance of credits to the customer or through cash payments to the customer, respectively. All other returns, rebates, and incentives are reflected as accrued expenses and settled through cash payments to the customer. Three wholesalers comprised 46%, 29%, and 21% of the Company’s gross revenue for the three months ended March 31, 2022. The following table summarizes activity in each of the Company’s product revenue provision and allowance categories as of March 31, 2022 (in thousands): Discounts and Chargebacks (1) Product Returns (2) Rebates and Incentives (3) Total Balance as of December 31, 2021 $ 249 $ 21 $ 1,110 $ 1,380 Provision related to current period revenue 272 10 1,092 1,374 Changes in estimate related to prior period revenue — — — — Credit/payments (122 ) — (1,040 ) (1,162 ) Balance as of March 31, 2022 $ 399 $ 31 $ 1,162 $ 1,592 (1) Discounts and chargebacks include fees for wholesaler fees, prompt pay and other discounts, and chargebacks. Discounts and chargebacks are deducted from gross revenue at the time revenues are recognized and are included as a reduction in accounts receivable or as an accrued expense based on their nature on the Company’s unaudited interim condensed consolidated balance sheet. (2) Provisions for product returns are deducted from gross revenues at the time revenues are recognized and are included in accrued expenses on the Company’s unaudited interim condensed consolidated balance sheet. (3) Rebates and incentives include rebates and co-pay program incentives. Provisions for rebates and incentives are deducted from gross revenues at the time revenues are recognized and are included in accrued expenses on License Agreement Revenue In February 2021, the Company entered into an Exclusive License and Collaboration Agreement (the “Agreement”) with Hansoh (Shanghai) Health Technology Co., Ltd., and Jiangsu Hansoh Pharmaceutical Group Company Limited (collectively, “ Hansoh ” ), pursuant to which the Company granted to Hansoh an exclusive license to research, develop and commercialize ibrexafungerp in the Greater China region, including mainland China, Hong Kong, Macau, and Taiwan (the “Territory”) . The Company also granted to Hansoh a non-exclusive license to manufacture ibrexafungerp solely for development and commercialization in the Territory. Under the terms of the Agreement, Hansoh shall be responsible for the development, regulatory approval and commercialization of ibrexafungerp in the Territory. Pursuant to the terms of the Agreement, the Company received as consideration for the licenses a nonrefundable upfront cash payment of $10.0 million and is entitled to an additional payment that was payable upon the transfer of certain data related to the manufacturing license. In addition, the Company will also be eligible to receive up to $110.0 million in potential development and commercial milestones. In addition, during the term of the licensing agreement, the Company is entitled to low double-digit royalties on net product sales. The obligation to pay royalties with respect to sales in a specified region will continue until the later of the date of expiration of all intellectual property and regulatory exclusivity for the product in the region and ten years from the first commercial sale, unless earlier terminated by Hansoh with advanced notice for convenience or under other specified circumstances. The Company is also eligible to receive a milestone related to the successful completion of a manufacturing batch by Hansoh. The Company evaluated the Agreement and concluded that it was subject to ASC 606 as the Company viewed the Agreement as a contract with a customer as the activities were central to its business operations. As such, the Company assessed the terms of the Agreement and identified one performance obligation for the licenses to research, develop, manufacture and commercialize ibrexafungerp in the Territory, including the underlying know-how related to such licenses. The Company also evaluated options for additional goods and services included in the Agreement related to (1) optional technical assistance related to development, regulatory or manufacturing activities and (2) an optional supply agreement for ibrexafungerp. Such options for additional goods or services were not considered to contain material rights as pricing approximated standalone selling prices and therefore the Company concluded that such options did not represent performance obligations and will be accounted for as separate transactions if and when they occur in the future. The Company determined that the transaction price of $12.1 million included the fixed upfront cash payment of $10.0 million, an additional amount that was payable upon the transfer of certain data related to the manufacturing license, and $1.1 million related to withholding tax obligations that Hansoh remitted on behalf of the Company. The remaining amounts related to the successful completion of a manufacturing batch by Hansoh and potential development milestones represent variable consideration as it was concluded that it was not probable that a significant reversal in cumulative revenue recognized will not occur and therefore not included in the transaction price as of March 31, 2021. Potential commercial milestones and royalties on net product sales will be recognized in the same period that the underlying net product sales occur as they were determined to relate to the license. The transaction price was recorded in license agreement revenue during the three months ended March 31, 2021 at a point in time upon control of the license transferring to Hansoh. The Company will reevaluate the transaction price at the end of each reporting period as uncertain events or resolved, or as other changes in circumstances occur. For the three months ended March 31, 2022, there was no license agreement revenue recognized given the variable consideration was fully constrained as of March 31, 2022 Additionally, pursuant to the Agreement, both the Company and Hansoh agreed to make reasonable efforts to account for applicable taxes, fees, duties, levies, or similar amounts imposed on net income, franchise taxes and profits arising directly or indirectly from the activities of the Agreement. To the extent Hansoh is required by applicable laws to withhold or deduct any tax on any payment to the Company, Hansoh agreed to make certain increases on payments to the Company to ensure that the Company receives a sum equal to what the Company would have received had there been no deduction or withholding. As a result, the Company has recorded revenue and tax withholding expense primarily associated with the up-front payment received by the Company on a gross basis. For the three months ended March 31, 2021, the Company recognized $1.1 million in license agreement revenue and $1.1 million in income tax expense to account for the tax withholding expense primarily on the $10.0 million up-front that the Company is responsible to remit under applicable tax law. In July 2016, the Company entered into an asset purchase agreement with UK-based Cypralis Limited (or "Cypralis"), a life sciences company, for the sale of its cyclophilin inhibitor assets. Cypralis also acquired all patents, patent applications and know-how related to the acquired portfolio. In connection with the asset purchase agreement, the Company is eligible to receive milestone payments upon the successful progression of Cypralis clinical candidates into later stage clinical studies and royalties payable upon product commercialization. The Company retains the right to repurchase the portfolio assets from Cypralis if abandoned or deprioritized. For the three months ended March 31, 2022 and 2021, there was no revenue recognized associated with this agreement given the variable consideration associated with the sale of intellectual property to Cypralis was fully constrained as of March 31, 2022 and 2021, respectively. Additionally, in October 2014 the Company entered into a license agreement with Waterstone Pharmaceutical HK Limited (or “Waterstone”) and granted Waterstone an exclusive, worldwide license to develop and commercialize certain non-strategic compounds. The Company is entitled to receive potential milestones and royalties from Waterstone; however, there was no revenue recognized by the Company associated with this agreement given the variable consideration was fully constrained as of March 31, 2022 and March 31, 2021 .

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2022
Subsequent Events [Abstract]
Subsequent Events	1 2 . Subsequent Events On April 22, 2022, the Company entered into an Equity Underwriting Agreement (the “Underwriting Agreement”) with Guggenheim Securities, LLC, as representative of the several underwriters (the “Underwriters”), relating to the offering, issuance and sale (the “Offering”) of (a) 3,333,333 shares of the Company’s common stock, par value $0.001 per share, (b) pre-funded warrants, in lieu of common stock, to purchase 11,666,667 shares of the Company’s common stock, par value $0.001 per share, and (c) warrants, which will accompany the common stock or pre-funded warrants, to purchase up to an aggregate of 15,000,000 shares of the Company’s common stock. The pre-funded warrants entitle the holders to purchase up to 11,666,667 shares of common stock and have an unlimited term and an exercise price of $0.001 per share. The warrants entitle the holders to purchase up to an aggregate of 15,000,000 shares of common stock and have a seven-year an additional provision entitling the holder thereof to purchase a pre-funded warrant rather than a share of common stock at the warrant exercise price less the exercise price of the pre-funded warrant purchased In addition, the Company granted to the Underwriters an option to purchase up 2,250,000 additional shares of common stock and/or warrants to purchase up to an aggregate of an additional 2,250,000 shares of common stock, in each case at their respective public offering prices, less underwriting discounts and commissions.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Basic and Diluted Net Loss per Share of Common Stock	Basic and Diluted Net Loss per Share of Common Stock The Company calculates net loss per common share in accordance with ASC Earnings Per Share Earnings Per Share, Three Months Ended March 31, 2022 2021 Net loss $ (5,451 ) $ (4,676 ) Dilutive effect of warrant liability — (1,323 ) Dilutive effect of convertible debt (584 ) — Net loss allocated to common shares $ (6,035 ) $ (5,999 ) Weighted average common shares outstanding – basic 32,051,228 25,802,700 Dilutive effect of warrant liability — 721,220 Dilutive effect of convertible debt 1,138,200 — Weighted average common shares outstanding – diluted 33,189,428 26,523,920 Net loss per share – diluted $ (0.18 ) $ (0.23 ) The following potentially dilutive shares of common stock have not been included in the computation of diluted net loss per share for the three months ended March 31, 2022 and 2021, as the result would be anti-dilutive: Three Months Ended March 31, 2022 2021 Outstanding stock options 2,050,094 1,371,606 Outstanding restricted stock units 981,841 96,974 Warrants to purchase common stock associated with June 2016 public offering — 421,867 Warrants to purchase common stock associated with March 2018 public offering – Series 2 798,810 798,810 Warrants to purchase common stock associated with December 2019 Public Offering — 4,472,205 Warrants to purchase common stock associated with December 2020 Public Offering - Series 2 6,800,000 6,800,000 Warrants to purchase common stock associated with Loan Agreement 198,819 — Warrants to purchase common stock associated with Solar loan agreement — 12,243 Common stock associated with March 2019 Notes — 1,138,200 Warrants to purchase common stock associated with Danforth 50,000 — Total 10,879,564 15,111,905
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). The amendments in ASU 2016-13 require a financial asset (or group of financial assets) measured at amortized cost basis to be presented at the net amount expected to be collected. In November 2019, the FASB issued ASU No. 2019-10, Financial Instruments – Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) (“ASU 2019-10”), which revised the effective dates for ASU 2016-13 for public business entities that meet the SEC definition of a smaller reporting company to fiscal years, and interim periods within those fiscal years, beginning after December 15, 2022, with early adoption permitted. As a smaller reporting company, the Company is currently evaluating the impact ASU 2016-13 will have on its unaudited interim condensed consolidated financial statements. In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options and Derivatives and Hedging—Contracts in Entity’s Own Equity: Accounting for Convertible Instruments and Contracts in and Entity’s Own Equity (“ASU 2020-06”). The amendments in ASU 2020-06 reduce the number of accounting models for convertible debt instruments and revises certain guidance relating to the derivative scope exception and earnings per share. The amendments in ASU 2020-06 are effective for public business entities that meet the definition of a SEC filer and a smaller reporting company for fiscal years beginning after December 15, 2023, and interim periods within those years. As a smaller reporting company, the Company is currently evaluating the impact ASU 2020-06 will have on its unaudited interim condensed consolidated financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Schedule of Diluted Net Loss Per Common Share	The Company calculates net loss per common share in accordance with ASC Earnings Per Share Earnings Per Share, Three Months Ended March 31, 2022 2021 Net loss $ (5,451 ) $ (4,676 ) Dilutive effect of warrant liability — (1,323 ) Dilutive effect of convertible debt (584 ) — Net loss allocated to common shares $ (6,035 ) $ (5,999 ) Weighted average common shares outstanding – basic 32,051,228 25,802,700 Dilutive effect of warrant liability — 721,220 Dilutive effect of convertible debt 1,138,200 — Weighted average common shares outstanding – diluted 33,189,428 26,523,920 Net loss per share – diluted $ (0.18 ) $ (0.23 )
Summary of Antidilutive Securities Excluded from Computation of Weighted Average Common Stock Outstanding	The following potentially dilutive shares of common stock have not been included in the computation of diluted net loss per share for the three months ended March 31, 2022 and 2021, as the result would be anti-dilutive: Three Months Ended March 31, 2022 2021 Outstanding stock options 2,050,094 1,371,606 Outstanding restricted stock units 981,841 96,974 Warrants to purchase common stock associated with June 2016 public offering — 421,867 Warrants to purchase common stock associated with March 2018 public offering – Series 2 798,810 798,810 Warrants to purchase common stock associated with December 2019 Public Offering — 4,472,205 Warrants to purchase common stock associated with December 2020 Public Offering - Series 2 6,800,000 6,800,000 Warrants to purchase common stock associated with Loan Agreement 198,819 — Warrants to purchase common stock associated with Solar loan agreement — 12,243 Common stock associated with March 2019 Notes — 1,138,200 Warrants to purchase common stock associated with Danforth 50,000 — Total 10,879,564 15,111,905

Prepaid Expenses and Other Cu_2

Prepaid Expenses and Other Current Assets (Tables)	3 Months Ended
	Mar. 31, 2022
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]
Schedule of Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets consisted of the following (in thousands): March 31, 2022 December 31, 2021 Prepaid research and development services $ 753 $ 247 Prepaid insurance 206 505 Other prepaid expenses 2,956 2,813 Other current assets 4 4 Total prepaid expenses and other current assets $ 3,919 $ 3,569

Inventory (Tables)

Inventory (Tables)	3 Months Ended
	Mar. 31, 2022
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventory consisted of the following (in thousands): March 31, 2022 December 31, 2021 Raw materials $ 5,486 $ 5,162 Work in process 3 3 Finished goods 115 127 Total inventory $ 5,604 $ 5,292

Accrued Expenses (Tables)

Accrued Expenses (Tables)	3 Months Ended
	Mar. 31, 2022
Payables And Accruals [Abstract]
Schedule of Accrued Expenses	Accrued expenses consisted of the following (in thousands): March 31, 2022 December 31, 2021 Accrued research and development expenses $ 1,210 $ 1,498 Accrued employee bonus compensation 505 2,012 Other accrued expenses 1,893 1,352 Accrued co-pay rebates 915 836 Total accrued expenses $ 4,523 $ 5,698

Borrowings (Tables)

Borrowings (Tables)	3 Months Ended
	Mar. 31, 2022
Debt Disclosure [Abstract]
Schedule of Future Principal Debt Payments On Currently Outstanding Loan Payable	Future principal debt payments on the currently outstanding loan payable as of March 31, 2022 are as follows (in thousands): 2021 $ — 2022 — 2023 — 2024 23,874 2025 11,126 Total principal payments 35,000 Final fee due at maturity 1,383 Total principal and final fee payment 36,383 Unamortized discount and debt issuance costs (2,670 ) Less current portion — Loan payable, long term $ 33,713

Commitments and Contingencies (

Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2022
Commitments And Contingencies Disclosure [Abstract]
Summary of Quantitative Information Associated with Amounts Recognized in Unaudited Condensed Consolidated Financial Statements for Lease	The following table summarizes certain quantitative information associated with the amounts recognized in the unaudited condensed consolidated financial statements for the Lease (dollars in thousands): Three Months Ended March 31, 2022 2021 Operating lease cost $ 166 $ 166 Variable lease cost (3 ) (2 ) Total operating lease expense $ 163 $ 164 Cash paid for amounts included in the measurement of operating lease liability $ 174 $ 170 March 31, 2022 December 31, 2021 Remaining Lease term (years) 7.34 7.59 Discount rate 15 % 15 %
Future Minimum Lease Payments	Future minimum lease payments for the Lease as of March 31, 2022 are as follows (in thousands): March 31, 2022 2022 $ 354 2023 715 2024 730 2025 744 2026 759 Thereafter 2,030 Total $ 5,332
Presentation of Operating Lease Liability	The presentations of the operating lease liability as of March 31, 2022 are as follows (in thousands): March 31, 2022 Present value of future minimum lease payments $ 3,215 Operating lease liability, current portion $ 77 Operating lease liability, long-term portion 3,138 Total operating lease liability $ 3,215 Difference between future minimum lease payments and discounted cash flows $ 2,117

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2022
Equity [Abstract]
Summary of Common Stock Shares Activity	The following table summarizes common stock share activity for the three months ended March 31, 2022 and 2021 (dollars in thousands): Three Months Ended March 31, 2022 Shares of Common Stock Common Stock Additional Paid-in Capital Accumulated Deficit Total Stockholders’ Equity Balance, December 31, 2021 28,705,334 $ 32 $ 400,705 $ (359,479 ) $ 41,258 Net loss — — — (5,451 ) (5,451 ) Stock-based compensation expense — — 922 — 922 Common stock issued, net of expenses 487,610 — 2,135 — 2,135 Common stock issued through employee stock purchase plan 3,120 — 10 — 10 Common stock issued for vested restricted stock units 25,094 — (18 ) — (18 ) Vested Loan Agreement warrants — — 71 71 Balance, March 31, 2022 29,221,158 $ 32 $ 403,825 $ (364,930 ) $ 38,927 Three Months Ended March 31, 2021 Shares of Common Stock Common Stock Additional Paid-in Capital Accumulated Deficit Total Stockholders’ Equity Balance, December 31, 2020 19,663,698 $ 20 $ 349,351 $ (326,613 ) $ 22,758 Net loss — — — (4,676 ) (4,676 ) Stock-based compensation expense — — 398 — 398 Common stock issued for conversion of April 2020 Notes 959,080 1 7,452 — 7,453 Common stock issued through employee stock purchase plan 2,184 — 6 — 6 Common stock issued for vested restricted stock units 675 — (15 ) — (15 ) Balance, March 31, 2021 20,625,637 $ 21 $ 357,192 $ (331,289 ) $ 25,924
Common Stock Reserved For Future Issuances	The Company had reserved shares of common stock for future issuance as follows: March 31, 2022 December 31, 2021 Outstanding stock options 2,050,094 1,542,126 Outstanding restricted stock units 981,841 133,834 Warrants to purchase common stock associated with March 2018 Public Offering – Series 2 798,810 798,810 Warrants to purchase common stock associated with December 2020 Public Offering - Series 2 6,800,000 6,800,000 Prefunded warrants to purchase common stock associated with December 2020 Public Offering 3,200,000 3,200,000 Warrants to purchase common stock associated with Loan Agreement 198,819 170,410 Warrant to purchase common stock associated with Danforth 50,000 50,000 For possible future issuance for the conversion of the March 2019 Notes 1,138,200 1,138,200 For possible future issuance under 2014 Plan (Note 9) 150,114 295,220 For possible future issuance under Employee Stock Purchase Plan 3,714 3,893 For possible future issuance under 2015 Plan (Note 9) 147,250 235,000 Total common shares reserved for future issuance 15,518,842 14,367,493

Stock-based Compensation (Table

Stock-based Compensation (Tables)	3 Months Ended
	Mar. 31, 2022
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock Option Activity	The activity for the Company’s 2009 Stock Option Plan, 2014 Plan, and 2015 Plan, for the three months ended March 31, 2022, is summarized as follows: Number of Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life (in years) Aggregate Intrinsic Value ($000) Outstanding — December 31, 2021 1,542,126 $ 14.89 7.45 $ 42 Granted 550,500 $ 4.59 Forfeited/Cancelled (42,532 ) $ 7.44 Outstanding — March 31, 2022 2,050,094 $ 12.28 7.97 $ — Exercisable — March 31, 2022 793,216 $ 21.77 6.01 $ — Vested or expected to vest — March 31, 2022 2,050,094 $ 12.28 7.97 $ —
Schedule of Restricted Stock Units ("RSU") Activity	Restricted stock unit (“RSU”) activity under the 2014 Plan and 2015 Plan for the three months ended March 31, 2022, is summarized as follows: Number of Shares Weighted Average Grant Date Fair Value Per Share Non-vested at December 31, 2021 133,834 $ 7.98 Granted 883,465 $ 5.59 Vested (25,094 ) $ 7.92 Forfeited (10,364 ) $ 7.60 Non-vested at March 31, 2022 981,841 $ 5.83
Stock-Based Compensation Expense Related to Stock Options	Stock-based compensation expense related to stock options is included in the following line items in the accompanying unaudited condensed consolidated statements of operations (in thousands): Three Months Ended March 31, 2022 2021 Research and development $ 285 $ 126 Selling, general and administrative 637 272 Total $ 922 $ 398

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2022
Fair Value Disclosures [Abstract]
Summary of Financial Instruments Measured on a Recurring Basis	The following table summarizes the conclusions reached as of March 31, 2022 and December 31, 2021 for financial instruments measured at fair value on a recurring basis (in thousands): Fair Value Hierarchy Classification Balance Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) March 31, 2022 Cash $ 621 $ 621 — — Restricted cash 218 218 — — Money market funds 94,589 94,589 — — Total assets $ 95,428 $ 95,428 — — Warrant liabilities $ 7,961 — — $ 7,961 Derivative liability 378 — — 378 Total liabilities $ 8,339 — — $ 8,339 December 31, 2021 Cash $ 310 $ 310 — — Restricted cash 218 218 — — Money market funds 104,187 104,187 — — Total assets $ 104,715 $ 104,715 — — Warrant liabilities $ 18,062 — — $ 18,062 Derivative liabilities 1,358 — — 1,358 Total liabilities $ 19,420 — — $ 19,420
Summary of Reconciliation of Beginning and Ending Balances for Liabilities Measured at Fair Value on Recurring Basis	A reconciliation of the beginning and ending balances for liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows (in thousands): Warrant Liabilities Balance – December 31, 2021 $ 18,062 Loan Agreement warrants (71 ) Gain adjustment to fair value (10,030 ) Balance – March 31, 2022 $ 7,961 Derivative Liabilities Balance – December 31, 2021 $ 1,358 Gain adjustment to fair value (980 ) Balance – March 31, 2022 $ 378

Revenue (Tables)

Revenue (Tables)	3 Months Ended
	Mar. 31, 2022
Revenue From Contract With Customer [Abstract]
Summary of Activity in Each of Product Revenue Provision and Allowance Categories	The following table summarizes activity in each of the Company’s product revenue provision and allowance categories as of March 31, 2022 (in thousands): Discounts and Chargebacks (1) Product Returns (2) Rebates and Incentives (3) Total Balance as of December 31, 2021 $ 249 $ 21 $ 1,110 $ 1,380 Provision related to current period revenue 272 10 1,092 1,374 Changes in estimate related to prior period revenue — — — — Credit/payments (122 ) — (1,040 ) (1,162 ) Balance as of March 31, 2022 $ 399 $ 31 $ 1,162 $ 1,592 (1) Discounts and chargebacks include fees for wholesaler fees, prompt pay and other discounts, and chargebacks. Discounts and chargebacks are deducted from gross revenue at the time revenues are recognized and are included as a reduction in accounts receivable or as an accrued expense based on their nature on the Company’s unaudited interim condensed consolidated balance sheet. (2) Provisions for product returns are deducted from gross revenues at the time revenues are recognized and are included in accrued expenses on the Company’s unaudited interim condensed consolidated balance sheet. (3) Rebates and incentives include rebates and co-pay program incentives. Provisions for rebates and incentives are deducted from gross revenues at the time revenues are recognized and are included in accrued expenses on

Description of Business and B_2

Description of Business and Basis of Preparation - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Accumulated deficit	$ 364,930		$ 359,479
Cash and cash equivalents	95,210		$ 104,484
Income tax benefit	4,700	$ (1,100)
New Jersey
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Income tax benefit	$ 4,700

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Additional Information (Detail)	Mar. 31, 2022shares
December 2020 Public Offering | Pre-funded Warrants
Subsidiary Sale Of Stock [Line Items]
Number of outstanding warrants issued to purchase common stock (in shares)	3,200,000

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Schedule of Diluted Net Loss Per Common Share (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Accounting Policies [Abstract]
Net loss	$ (5,451)	$ (4,676)
Dilutive effect of warrant liability	0	(1,323)
Dilutive effect of convertible debt	(584)	0
Net loss allocated to common shares	$ (6,035)	$ (5,999)
Weighted average common shares outstanding – basic	32,051,228	25,802,700
Dilutive effect of warrant liability	0	721,220
Dilutive effect of convertible debt	1,138,200	0
Weighted average common shares outstanding – diluted	33,189,428	26,523,920
Net loss per share – diluted	$ (0.18)	$ (0.23)

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Shares (Detail) - shares	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	10,879,564	15,111,905
Outstanding stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	2,050,094	1,371,606
Outstanding restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	981,841	96,974
Warrants to purchase common stock associated with June 2016 Public Offering | Warrant
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	0	421,867
March 2018 Public Offering Series 2 | Warrant
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	798,810	798,810
December 2019 Public Offering | Warrant
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	0	4,472,205
December 2020 Public Offering Series 2 | Warrant
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	6,800,000	6,800,000
Warrants to purchase common stock associated with Loan Agreement | Warrant
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	198,819	0
Warrants to purchase common stock associated with Solar loan agreement | Warrant
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	0	12,243
Common stock associated with March 2019 Notes
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	0	1,138,200
Warrants to purchase common stock associated with Danforth | Warrant
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	50,000	0

Prepaid Expenses and Other Cu_3

Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Detail) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]
Prepaid research and development services	$ 753	$ 247
Prepaid insurance	206	505
Other prepaid expenses	2,956	2,813
Other current assets	4	4
Total prepaid expenses and other current assets	$ 3,919	$ 3,569

Inventory - Schedule of Invento

Inventory - Schedule of Inventory (Detail) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Inventory Disclosure [Abstract]
Raw materials	$ 5,486	$ 5,162
Work in process	3	3
Finished goods	115	127
Total inventory	$ 5,604	$ 5,292

Inventory - Additional Informat

Inventory - Additional Information (Detail) - USD ($) $ in Millions	Mar. 31, 2022	Dec. 31, 2021
Other Assets
Inventory [Line Items]
Raw material classified as long term	$ 4.5	$ 4.8

Accrued Expenses - Schedule of

Accrued Expenses - Schedule of Accrued Expenses (Detail) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Payables And Accruals [Abstract]
Accrued research and development expenses	$ 1,210	$ 1,498
Accrued employee bonus compensation	505	2,012
Other accrued expenses	1,893	1,352
Accrued co-pay rebates	915	836
Total accrued expenses	$ 4,523	$ 5,698

Borrowings - Additional Informa

Borrowings - Additional Information (Detail)	May 13, 2021USD ($)Tranche	Apr. 09, 2020USD ($)	Mar. 07, 2019USD ($)d$ / shares	Jan. 31, 2021USD ($)shares	Mar. 31, 2022USD ($)	Mar. 31, 2021USD ($)	Dec. 31, 2021USD ($)	Jun. 30, 2021USD ($)
Debt Instrument [Line Items]
Face amount					$ 36,383,000
Loss on extinguishment of debt					0	$ 2,725,000
Net carrying amount of convertible debt and derivative liability					10,817,000		$ 11,607,000
Amortization of debt issuance costs and discount					390,000	256,000
Deferred offering costs					124,000		150,000
Repayment of deferred fee, 2023					0
Repayment of deferred fee, 2024					23,874,000
Repayment of deferred fee, 2025					11,126,000
Other Liabilities
Debt Instrument [Line Items]
Deferred offering costs					$ 4,100,000		3,300,000
Interest rate, deferred fees					12.75%
Percentage of repayment of deferred fee, 2023					15.00%
Percentage of repayment of deferred fee, 2024					50.00%
Percentage of repayment of deferred fee, 2025					35.00%
Repayment of deferred fee, 2023					$ 700,000
Repayment of deferred fee, 2024					2,100,000
Repayment of deferred fee, 2025					1,500,000
Success premium					0	0
SVB
Debt Instrument [Line Items]
Minimum outstanding term loan principal percentage for financial covenant waived	50.00%
Loan and Security Agreement
Debt Instrument [Line Items]
Fair value of loan payable					$ 33,100,000		29,200,000
Loan and Security Agreement | Level 3 Inputs | Secured Spread
Debt Instrument [Line Items]
Debt instrument, measurement input					9.63
Loan and Security Agreement | Level 3 Inputs | Risk Free Rate
Debt Instrument [Line Items]
Debt instrument, measurement input					2.44
Loan and Security Agreement | Level 3 Inputs | Secured Yield
Debt Instrument [Line Items]
Debt instrument, measurement input					12.07
Term Loan | Loan and Security Agreement
Debt Instrument [Line Items]
Notes maturity date	Mar. 3, 2025
Basis spread on variable rate (as a percent)	9.05%
Debt instrument maturity date subject to occurrence of certain conditions	May 1, 2025
Term Loan | Loan and Security Agreement | Prime Rate
Debt Instrument [Line Items]
Basis spread on variable rate (as a percent)	5.80%
Term Loan | Loan and Security Agreement | Hercules Capital Inc. and Silicon Valley Bank
Debt Instrument [Line Items]
Face amount	$ 60,000,000
Number of available tranches | Tranche	4
Initial Tranche of Term Loan | Loan and Security Agreement
Debt Instrument [Line Items]
Additional borrowing amount available	$ 20,000,000
Second Tranche of Term Loan
Debt Instrument [Line Items]
Face amount								$ 10,000,000
Second Tranche of Term Loan | Loan and Security Agreement
Debt Instrument [Line Items]
Additional borrowing amount available	10,000,000
Third Tranche of Term Loan
Debt Instrument [Line Items]
Face amount					$ 5,000,000
Third Tranche of Term Loan | Loan and Security Agreement
Debt Instrument [Line Items]
Additional borrowing amount available	5,000,000
Fourth Tranche of Term Loan | Loan and Security Agreement
Debt Instrument [Line Items]
Additional borrowing amount available	25,000,000
Increment debt amount	$ 5,000,000
April 2020 Note Purchase Agreement
Debt Instrument [Line Items]
Face amount		$ 10,000,000
Date of issuance and sale of notes		Apr. 9, 2020
Proceeds from debt, net of issuance costs		$ 9,500,000
Payment of debt issuance costs		$ 500,000
Conversion of convertible note, amount				$ 6,000,000
Conversion of convertible note exchanged for shares | shares				959,080
Loss on extinguishment of debt				$ 2,700,000
Net carrying amount of convertible debt and derivative liability				4,800,000
Fair value of the consideration issued				$ 7,500,000
Senior Convertible Note Purchase Agreement
Debt Instrument [Line Items]
Face amount			$ 16,000,000
Notes maturity date			Mar. 15, 2025
Date of issuance and sale of notes			Mar. 7, 2019
Proceeds from debt, net of issuance costs			$ 14,700,000
Payment of debt issuance costs			$ 1,300,000
Senior convertible notes					10,400,000		10,200,000
Unamortized debt issuance cost					300,000
Bifurcated embedded conversion option derivative liability					400,000		1,400,000
Derivative, fair value					7,000,000
Gain on fair value adjustment of derivative liability					1,000,000	42,000
Amortization of debt issuance costs and discount					200,000	$ 300,000
Fair value of convertible debt and derivative liability					$ 10,900,000		$ 12,300,000
Purchase price as percentage of principal amount			100.00%
Interest rate			6.00%
Payment terms					The March 2019 Notes bear interest at a rate of 6.0% per annum payable semiannually in arrears on March 15 and September 15 of each year, beginning September 15, 2019. The March 2019 Notes will mature on March 15, 2025, unless earlier converted, redeemed or repurchased.
Conversion terms					holder of the March 2019 Notes may convert their March 2019 Notes at their option at any time prior to the close of business on the business day immediately preceding March 15, 2025 into shares of the Company’s common stock.
Conversion rate, number of shares to be issued per $1000 of principal (in shares)			73.9096
Principal amount of notes used as the denominator for conversion into notes			$ 1,000
Initial conversion price of notes | $ / shares			$ 13.53
Conversion rate, number of shares to be issued per $1000 of principal (in shares) after adjustment to certain events			81
Principal amount of notes used as the denominator for conversion into notes after adjustment of certain events			$ 1,000
Convertible notes, redemption start date			Mar. 15, 2022
Convertible notes, threshold percentage of stock price trigger			130.00%
Convertible notes, threshold trading days | d			20
Convertible notes, threshold consecutive trading days | d			30
Redemption price as percentage of the principal amount			100.00%
Redemption price as percentage of the principal amount subject to certain exceptions			100.00%

Borrowings - Schedule of Future

Borrowings - Schedule of Future Principal Debt Payments On Currently Outstanding Loan Payable (Detail) $ in Thousands	Mar. 31, 2022USD ($)
Debt Disclosure [Abstract]
2021	$ 0
2022	0
2023	0
2024	23,874
2025	11,126
Total principal payments	35,000
Final fee due at maturity	1,383
Total principal and final fee payment	36,383
Unamortized discount and debt issuance costs	(2,670)
Less current portion	0
Loan payable, long term	$ 33,713

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail)	Mar. 01, 2018USD ($)ft²	Mar. 31, 2022USD ($)	Mar. 31, 2021USD ($)
Commitment And Contingencies [Line Items]
Long-term lease agreement, area of office space | ft²	19,275
Lease term	11 years
Total lease payments	$ 7,300,000	$ 174,000	$ 170,000
Lessee, operating lease, existence of option to extend	true
Renewal term	5 years
Renewal term, description		The Company has the option to renew for two consecutive five-year periods from the end of the first term and the Company is not reasonably certain that the option to renew the Lease will be exercised. Under the Lease, the Company furnished a security deposit in the form of a standby letter of credit in the amount of $0.3 million, which was reduced by fifty-five thousand dollars on the first anniversary of the commencement date.  The security deposit will continue to be reduced by fifty-five thousand dollars every two years on the commencement date anniversary for eight years.
Security deposit in the form of a standby letter of credit	$ 300,000
Decrease in security deposit	$ 55,000
Maximum
Commitment And Contingencies [Line Items]
Milestone payments from the Company		$ 19,000,000

Commitments and Contingencies_2

Commitments and Contingencies - Summary of Quantitative Information Associated with Amounts Recognized in Unaudited Condensed Consolidated Financial Statements for Lease (Detail) - USD ($) $ in Thousands	Mar. 01, 2018	Mar. 31, 2022	Mar. 31, 2021
Commitments And Contingencies Disclosure [Abstract]
Operating lease cost		$ 166	$ 166
Variable lease cost		(3)	(2)
Total operating lease expense		163	164
Total lease payments	$ 7,300	$ 174	$ 170
Remaining Lease term (years)		7 years 4 months 2 days	7 years 7 months 2 days
Discount rate		15.00%	15.00%

Commitments and Contingencies_3

Commitments and Contingencies - Future Minimum Lease Payments (Detail) $ in Thousands	Mar. 31, 2022USD ($)
Commitments And Contingencies Disclosure [Abstract]
2022	$ 354
2023	715
2024	730
2025	744
2026	759
Thereafter	2,030
Total	$ 5,332

Commitments and Contingencies_4

Commitments and Contingencies - Presentation of Operating Lease Liability (Detail) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Commitments And Contingencies Disclosure [Abstract]
Present value of future minimum lease payments	$ 3,215
Operating lease liability, current portion	77	$ 70
Operating lease liability, long-term portion	3,138	$ 3,204
Total operating lease liability	3,215
Difference between future minimum lease payments and discounted cash flows	$ 2,117

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) $ / shares in Units, $ in Thousands	Apr. 10, 2020USD ($)$ / sharesshares	Jun. 30, 2021USD ($)shares	Mar. 31, 2022USD ($)$ / sharesshares	Mar. 31, 2021USD ($)	Dec. 31, 2021USD ($)$ / sharesshares	May 31, 2021$ / sharesshares
Schedule Of Capitalization Equity [Line Items]
Common stock, par value (in dollars per share) | $ / shares			$ 0.001		$ 0.001
Common stock, shares authorized (in shares) | shares			100,000,000		100,000,000
Common stock, shares issued (in shares) | shares			29,221,158		28,705,334
Common stock, shares outstanding (in shares) | shares			29,221,158		28,705,334
Proceeds from common stock issued			$ 2,164	$ 0
Warrant liabilities fair value adjustment			10,030	1,296
Warrant liabilities			$ 8,000		$ 18,100
Debt instrument, description			0
Face amount			$ 36,383
Reclass of warrant liability to additional paid in capital			71	$ 0
Second Tranche of Term Loan
Schedule Of Capitalization Equity [Line Items]
Face amount		$ 10,000
Reclass of warrant liability to additional paid in capital		$ 300
Third Tranche of Term Loan
Schedule Of Capitalization Equity [Line Items]
Face amount			5,000
Reclass of warrant liability to additional paid in capital			$ 100
Loan and Security Agreement | Hercules Capital Inc. and Silicon Valley Bank
Schedule Of Capitalization Equity [Line Items]
Common stock, par value (in dollars per share) | $ / shares						$ 0.001
Multiplier value by aggregate amount of the term loan advances divided by exercise price of warrants to calculate number of shares for purchase						0.04
Number of warrants issued to purchase common stock (in shares) | shares						113,607
Loan and Security Agreement | Second Tranche of Term Loan | Hercules Capital Inc. and Silicon Valley Bank
Schedule Of Capitalization Equity [Line Items]
Common stock, shares issued (in shares) | shares		56,803
Loan and Security Agreement | Third Tranche of Term Loan | Hercules Capital Inc. and Silicon Valley Bank
Schedule Of Capitalization Equity [Line Items]
Common stock, shares issued (in shares) | shares			28,409
Aspire Capital | Common Stock Purchase Agreement
Schedule Of Capitalization Equity [Line Items]
Number of purchase aggregate shares of common stock | shares	1,956,547
Percentage of common stock outstanding	19.99%
Number of shares committed | shares	70,910
Average purchase price of shares sold | $ / shares	$ 8.461
Percentage of common stock owned	19.99%
Common stock issued, net of expenses (in shares) | shares			350,000
Proceeds from common stock issued			$ 1,500
Aspire Capital | Common Stock Purchase Agreement | Maximum
Schedule Of Capitalization Equity [Line Items]
Sale of common stock at sole discretion	$ 20,000
Cantor Fitzgerald & Co. and Ladenburg Thalmann & Co. Inc. | Sales Agreement
Schedule Of Capitalization Equity [Line Items]
Common stock issued, net of expenses (in shares) | shares			137,610
Proceeds from common stock issued			$ 700

Stockholders' Equity - Summary

Stockholders' Equity - Summary of Common Stock Shares Activity (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Common Stock Outstanding Roll Forward [Roll Forward]
Beginning balance	$ 41,258	$ 22,758
Beginning balance (in shares)	28,705,334
Net loss	$ (5,451)	(4,676)
Stock-based compensation expense	922	398
Common stock issued, net of expenses	2,135
Common stock issued through employee stock purchase plan	10	6
Common stock issued for vested restricted stock units	(18)	(15)
Vested Loan Agreement warrants	71
Ending balance	$ 38,927	25,924
Ending balance (in shares)	29,221,158
April 2020 Notes
Common Stock Outstanding Roll Forward [Roll Forward]
Common stock issued for conversion of Notes		7,453
Common Stock
Common Stock Outstanding Roll Forward [Roll Forward]
Beginning balance	$ 32	$ 20
Beginning balance (in shares)	28,705,334	19,663,698
Net loss	$ 0	$ 0
Stock-based compensation expense	0	0
Common stock issued, net of expenses	$ 0
Common stock issued, net of expenses (in shares)	487,610
Common stock issued through employee stock purchase plan	$ 0	$ 0
Common stock issued through employee stock purchase (in shares)	3,120	2,184
Common stock issued for vested restricted stock units	$ 0	$ 0
Common stock issued for vested restricted stock units (in shares)	25,094	675
Vested Loan Agreement warrants	$ 0
Ending balance	$ 32	$ 21
Ending balance (in shares)	29,221,158	20,625,637
Common Stock | April 2020 Notes
Common Stock Outstanding Roll Forward [Roll Forward]
Common stock issued for conversion of Notes		$ 1
Common stock issued for conversion of Notes (in shares)		959,080
Additional Paid-in Capital
Common Stock Outstanding Roll Forward [Roll Forward]
Beginning balance	$ 400,705	$ 349,351
Net loss	0	0
Stock-based compensation expense	922	398
Common stock issued, net of expenses	2,135
Common stock issued through employee stock purchase plan	10	6
Common stock issued for vested restricted stock units	(18)	(15)
Vested Loan Agreement warrants	71
Ending balance	403,825	357,192
Additional Paid-in Capital | April 2020 Notes
Common Stock Outstanding Roll Forward [Roll Forward]
Common stock issued for conversion of Notes		7,452
Accumulated Deficit
Common Stock Outstanding Roll Forward [Roll Forward]
Beginning balance	(359,479)	(326,613)
Net loss	(5,451)	(4,676)
Stock-based compensation expense	0	0
Common stock issued, net of expenses	0
Common stock issued through employee stock purchase plan	0	0
Common stock issued for vested restricted stock units	0	0
Vested Loan Agreement warrants	0
Ending balance	$ (364,930)	(331,289)
Accumulated Deficit | April 2020 Notes
Common Stock Outstanding Roll Forward [Roll Forward]
Common stock issued for conversion of Notes		$ 0

Stockholders' Equity - Schedule

Stockholders' Equity - Schedule of Reserved Shares of Common Stock for Future Issuance (Detail) - shares	Mar. 31, 2022	Dec. 31, 2021
Class of Stock [Line Items]
Common shares reserved for future issuance	15,518,842	14,367,493
Stock options
Class of Stock [Line Items]
Common shares reserved for future issuance	2,050,094	1,542,126
Restricted Stock Units
Class of Stock [Line Items]
Common shares reserved for future issuance	981,841	133,834
Warrant | March 2018 Public Offering
Class of Stock [Line Items]
Common shares reserved for future issuance	798,810	798,810
Warrant | December 2020 Public Offering Series 2
Class of Stock [Line Items]
Common shares reserved for future issuance	6,800,000	6,800,000
Warrant | Prefunded Warrants to Purchase Common Stock Associated with December 2020 Public Offering
Class of Stock [Line Items]
Common shares reserved for future issuance	3,200,000	3,200,000
Warrant | Warrant to purchase common stock associated with Danforth
Class of Stock [Line Items]
Common shares reserved for future issuance	50,000	50,000
Warrant | Warrants to purchase common stock associated with Loan Agreement
Class of Stock [Line Items]
Common shares reserved for future issuance	198,819	170,410
March 2019 Notes
Class of Stock [Line Items]
Common shares reserved for future issuance	1,138,200	1,138,200
2014 Employee Stock Purchase Plan
Class of Stock [Line Items]
Common shares reserved for future issuance	3,714	3,893
2014 Plan
Class of Stock [Line Items]
Common shares reserved for future issuance	150,114	295,220
2015 Plan
Class of Stock [Line Items]
Common shares reserved for future issuance	147,250	235,000

Stock-based Compensation - 2014

Stock-based Compensation - 2014 Equity Incentive Plan (Detail) - 2014 Equity Incentive Plan - shares	Jan. 01, 2022	Jan. 01, 2021	Mar. 31, 2022
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, number of additional shares authorized	1,148,213	786,547
Possible future issuance under equity compensation plan (in shares)			150,114

Stock-based Compensation - 2015

Stock-based Compensation - 2015 Inducement Award Plan (Detail) - shares	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Apr. 30, 2021	Apr. 29, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Option to purchase (shares)	550,500
2015 Inducement Award Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Possible future issuance under equity compensation plan (in shares)	147,250
Option to purchase (shares)	69,000	0
Shares authorized under the plan (in shares)			500,000	90,000

Stock-based Compensation - Stoc

Stock-based Compensation - Stock Option Activity (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Number of Shares
Beginning balance - Outstanding (shares)	1,542,126
Granted (shares)	550,500
Forfeited/Cancelled (shares)	(42,532)
Ending balance - Outstanding (shares)	2,050,094	1,542,126
Exercisable (shares)	793,216
Vested or expected to vest (shares)	2,050,094
Weighted- Average Exercise Price
Beginning balance - Outstanding (in dollars per share)	$ 14.89
Granted (in dollars per share)	4.59
Forfeited/Cancelled (in dollars per share)	7.44
Ending balance - Outstanding (in dollars per share)	12.28	$ 14.89
Exercisable (in dollars per share)	21.77
Vested or expected to vest (in dollars per share)	$ 12.28
Weighted- Average Remaining Contractual Life (in years)
Balance - Outstanding	7 years 11 months 19 days	7 years 5 months 12 days
Exercisable	6 years 3 days
Vested or expected to vest	7 years 11 months 19 days
Aggregate Intrinsic Value ($000)
Balance - Outstanding	$ 0	$ 42
Exercisable	0
Vested and expected to vest	$ 0

Stock-based Compensation - Sche

Stock-based Compensation - Schedule of Restricted Stock Units ("RSU") Activity (Detail) - Outstanding restricted stock units	3 Months Ended
	Mar. 31, 2022$ / sharesshares
Number of Shares
Beginning balance - Outstanding (shares) | shares	133,834
Options granted in period (shares) | shares	883,465
Vested (shares) | shares	(25,094)
Forfeited (shares) | shares	(10,364)
Ending balance - Outstanding (shares) | shares	981,841
Weighted Average Grant Date Fair Value Per Share
Beginning balance - Outstanding (in dollars per share) | $ / shares	$ 7.98
Granted (in dollars per share) | $ / shares	5.59
Vested (in dollars per share) | $ / shares	7.92
Forfeited (in dollars per share) | $ / shares	7.60
Ending balance - Outstanding (in dollars per share) | $ / shares	$ 5.83
Vesting percentage	25.00%
Vesting period of options	4 years

Stock-based Compensation - Comp

Stock-based Compensation - Compensation Cost (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-based compensation expense	$ 922,000	$ 398,000
Tax benefit from compensation expense	$ 0	$ 0

Stock-based Compensation - St_2

Stock-based Compensation - Stock-Based Compensation Expense Related to Stock Options (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense	$ 922	$ 398
Research and development
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense	285	126
Selling, general and administrative
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense	$ 637	$ 272

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Financial Instruments Measured on a Recurring Basis (Detail) - Fair Value, Measurements, Recurring - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Fair value of financial assets	$ 95,428	$ 104,715
Fair value of financial liabilities	8,339	19,420
Warrant liabilities
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Fair value of financial liabilities	7,961	18,062
Derivative liabilities
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Fair value of financial liabilities	378	1,358
Cash
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Fair value of financial assets	621	310
Restricted cash
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Fair value of financial assets	218	218
Money market funds
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Fair value of financial assets	94,589	104,187
Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Fair value of financial assets	95,428	104,715
Fair value of financial liabilities	0	0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Warrant liabilities
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Fair value of financial liabilities	0	0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Derivative liabilities
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Fair value of financial liabilities	0	0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Cash
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Fair value of financial assets	621	310
Quoted Prices in Active Markets for Identical Assets (Level 1) | Restricted cash
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Fair value of financial assets	218	218
Quoted Prices in Active Markets for Identical Assets (Level 1) | Money market funds
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Fair value of financial assets	94,589	104,187
Significant Other Observable Inputs (Level 2)
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Fair value of financial assets	0	0
Fair value of financial liabilities	0	0
Significant Other Observable Inputs (Level 2) | Warrant liabilities
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Fair value of financial liabilities	0	0
Significant Other Observable Inputs (Level 2) | Derivative liabilities
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Fair value of financial liabilities	0	0
Significant Other Observable Inputs (Level 2) | Cash
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Fair value of financial assets	0	0
Significant Other Observable Inputs (Level 2) | Restricted cash
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Fair value of financial assets	0	0
Significant Other Observable Inputs (Level 2) | Money market funds
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Fair value of financial assets	0	0
Significant Unobservable Inputs (Level 3)
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Fair value of financial assets	0	0
Fair value of financial liabilities	8,339	19,420
Significant Unobservable Inputs (Level 3) | Warrant liabilities
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Fair value of financial liabilities	7,961	18,062
Significant Unobservable Inputs (Level 3) | Derivative liabilities
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Fair value of financial liabilities	378	1,358
Significant Unobservable Inputs (Level 3) | Cash
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Fair value of financial assets	0	0
Significant Unobservable Inputs (Level 3) | Restricted cash
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Fair value of financial assets	0	0
Significant Unobservable Inputs (Level 3) | Money market funds
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Fair value of financial assets	$ 0	$ 0

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail) - Significant Unobservable Inputs (Level 3)	Mar. 31, 2022
Stock Price Volatility
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Derivative liabilities, unobservable inputs rate	61.4
Stock Price Volatility | Minimum
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Warrant liabilities, stock price volatility rate	81.7
Stock Price Volatility | Maximum
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Warrant liabilities, stock price volatility rate	84.1
Stock Price Volatility | Weighted Average
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Warrant liabilities, stock price volatility rate	84.1
Market Credit Spread
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Derivative liabilities, unobservable inputs rate	1,463
Estimated Yield
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Derivative liabilities, unobservable inputs rate	17.1
Discounts for Lack of Marketability | March 2019 Notes
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Senior convertible notes, unobservable inputs rate	2.9

Fair Value Measurements - Sum_2

Fair Value Measurements - Summary of Reconciliation of Beginning and Ending Balances for Liabilities Measured at Fair Value on Recurring Basis (Detail) $ in Thousands	3 Months Ended
	Mar. 31, 2022USD ($)
Warrant liabilities
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning balance	$ 18,062
Loan Agreement warrants	(71)
Gain (loss) adjustment to fair value	(10,030)
Ending balance	7,961
Derivative liabilities
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning balance	1,358
Gain (loss) adjustment to fair value	(980)
Ending balance	$ 378

Revenue - Additional Informatio

Revenue - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Disaggregation Of Revenue [Line Items]
Revenue	$ 687,000	$ 12,050,000
Income tax expense	(4,700,000)	1,100,000
Exclusive License And Collaboration Agreement
Disaggregation Of Revenue [Line Items]
Non refundable upfront payment received	10,000,000
Transaction price	12,100,000
Fixed upfront cash payment	10,000,000	10,000,000
Amount related to withholding tax obligations	1,100,000
Revenue recognized	0	1,100,000
Income tax expense		1,100,000
Exclusive License And Collaboration Agreement | Maximum
Disaggregation Of Revenue [Line Items]
Potential development and commercial milestones yet to receive	110,000,000
Asset Purchase Agreement | Cypralis Limited
Disaggregation Of Revenue [Line Items]
Revenue recognized	0	0
License Agreement | Waterstone Pharmaceutical HK Limited
Disaggregation Of Revenue [Line Items]
Revenue recognized	$ 0	0
Sales Revenue Net | Customer Concentration Risk | Wholesaler One
Disaggregation Of Revenue [Line Items]
Percentage of gross revenue	46.00%
Sales Revenue Net | Customer Concentration Risk | Wholesaler Two
Disaggregation Of Revenue [Line Items]
Percentage of gross revenue	29.00%
Sales Revenue Net | Customer Concentration Risk | Wholesaler Three
Disaggregation Of Revenue [Line Items]
Percentage of gross revenue	21.00%
Product Revenue, Net
Disaggregation Of Revenue [Line Items]
Revenue	$ 687,000	$ 0

Revenue - Summary of Activity i

Revenue - Summary of Activity in Each of Product Revenue Provision and Allowance Categories (Detail) $ in Thousands	3 Months Ended
	Mar. 31, 2022USD ($)
Disaggregation Of Revenue [Line Items]
Balance	$ 1,380
Provision related to current period revenue	1,374
Changes in estimate related to prior period revenue	0
Credit/payments	(1,162)
Balance	1,592
Discounts and Chargebacks
Disaggregation Of Revenue [Line Items]
Balance	249
Provision related to current period revenue	272
Changes in estimate related to prior period revenue	0
Credit/payments	(122)
Balance	399
Product Returns
Disaggregation Of Revenue [Line Items]
Balance	21
Provision related to current period revenue	10
Changes in estimate related to prior period revenue	0
Credit/payments	0
Balance	31
Rebates and Incentives
Disaggregation Of Revenue [Line Items]
Balance	1,110
Provision related to current period revenue	1,092
Changes in estimate related to prior period revenue	0
Credit/payments	(1,040)
Balance	$ 1,162

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	Apr. 22, 2022	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Subsequent Event [Line Items]
Common stock, par value (in dollars per share)		$ 0.001		$ 0.001
Proceeds from common stock issued		$ 2,164	$ 0
Equity Underwriting Agreement | Subsequent Event
Subsequent Event [Line Items]
Common stock issued, net of expenses (in shares)	3,333,333
Common stock, par value (in dollars per share)	$ 0.001
Proceeds from common stock issued	$ 41,900
Equity Underwriting Agreement | Subsequent Event | Underwriters | Maximum
Subsequent Event [Line Items]
Number of warrants issued to purchase common stock (in shares)	2,250,000
Option to purchase shares of common stock	2,250,000
Pre-funded Warrants | Equity Underwriting Agreement | Subsequent Event
Subsequent Event [Line Items]
Common stock, par value (in dollars per share)	$ 0.001
Number of warrants issued to purchase common stock (in shares)	11,666,667
Public offering price	$ 2.999
Pre-funded Warrants | Equity Underwriting Agreement | Subsequent Event | Underwriters
Subsequent Event [Line Items]
Public offering price	2.81906
Series 2 Warrant | Equity Underwriting Agreement | Subsequent Event
Subsequent Event [Line Items]
Exercise price of warrants (in dollars per share)	$ 3.45
Warrant term	7 years
Series 2 Warrant | Equity Underwriting Agreement | Subsequent Event | Maximum
Subsequent Event [Line Items]
Number of warrants issued to purchase common stock (in shares)	15,000,000
Number of shares received per warrant (in shares)	15,000,000
Series 1 Warrant | Equity Underwriting Agreement | Subsequent Event
Subsequent Event [Line Items]
Exercise price of warrants (in dollars per share)	$ 0.001
Series 1 Warrant | Equity Underwriting Agreement | Subsequent Event | Maximum
Subsequent Event [Line Items]
Number of warrants issued to purchase common stock (in shares)	11,666,667
Common Stock
Subsequent Event [Line Items]
Common stock issued, net of expenses (in shares)		487,610
Common Stock | Equity Underwriting Agreement | Subsequent Event
Subsequent Event [Line Items]
Public offering price	$ 3
Common Stock | Equity Underwriting Agreement | Subsequent Event | Underwriters
Subsequent Event [Line Items]
Public offering price	$ 2.82